LOGO
Search
Search
Cancel
搜索
Search

Featured Products

NGS Library Prep kits

Molecular Research

Drug Discovery

Latest activity

New 2021-07-30

New Product Launching | Delta Plus & Lambda pseudovirus

With the evolution of the pandemic, the coronavirus is still mutating, causing trouble in the prevention work. These variants can lead to changes in the transmissibility, pathogenicity and immunogenicity of the virus. The World Health Organization (WHO) divides these mutant strains into “variant of concern” (VOC) and “variant of interest” (VOI), according to their difference in transmissibility and pathogenicity.
Learn more
What 2021-07-28

What is the Magic of High-Fidelity DNA Polymerase?

In order to help you in completing PCR experiments better and faster, Vazyme is pleased to introduce fast high-fidelity polymerase. Check by cliking links below  P510 https://lnkd.in/dqd95P8  P520 https://lnkd.in/dVUSCrT
Learn more
COVID-19 2021-06-29

COVID-19 Neutralizing Antibody Test Solution

At present, outbreaks of the India variant (B.1.617.2) have been confirmed in the United Kingdom, China, the United States, Africa and Pacific Rim countries. Studies have shown that it seems to spread more easily and lead to more serious diseases. Countries all over the world are actively carrying forward COVID-19 vaccination in order to achieve mass immunization as soon as possible. With the advent of the post-pandemic era, the vaccination rates in China and abroad are continuously increasing. As of May 2021, a number of COVID-19 vaccines have been approved for marketing in China, including inactivated virus vaccines, subunit vaccines and recombinant adenovirus expression vaccines. At present, the protective efficacy data results of all Chinese COVID-19 vaccines approved for conditional marketing met the relevant technical standards of the World Health Organization and relevant national technical standards. As of June 16, 2021, a total of 2.13 billion doses of COVID-19 vaccines have been injected, with 27.3 doses per 100 people; 900 million doses of COVID-19 vaccines have been injected in China, with 62.82 doses per 100 people. The effect of COVID-19 vaccination and evaluation of effects have become the focus of public attention. NextSARS-CoV-2, its vaccines and neutralizing antibodies are introduced:
Learn more
Vazyme 2021-06-28

Vazyme stand out at MEDLAB in Dubai

Medlab Middle East and Arab Health co-hosted MEDLAB in Dubai International Exhibition Center, UAE. The exhibition attracted more than 650 well-known companies and 35,000 visitors from more than 40 countries. Vazyme, as a R&D and innovative enterprise with both independent and controllable upstream technology development capabilities and terminal production capabilities brought Covid-19 related diagnosis and treatment solutions, POCT in vitro diagnostic related products and upstream raw materials and other products were unveiled.
Learn more

About  Us

 

about us

As a biotechnology company, Vazyme is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials. Relying on self-established critical generic technology platform, Vazyme successively marched into various business area: biological research, in vitro diagnosis (IVD), bio-pharmaceutical and so on. Moreover, our company is regarded as one of the few domestic R&D innovative enterprises that have capabilities of both independent and controllable upstream technology development and terminal product production. With “biochip” made in China, Vazyme is ready to provide source power for biotechnology industry. 

 

Distributors

The products on this website may not be sold in all countries or regions. Please contact Vazyme or your local distributor for further information.

这是描述信息

Address: Floor 1-3, Building C2, Red Maple Technology Industrial Park, Kechuang Road Economy & Technology Development Zone, Nanjing, China.

Copyright 2015 Vazyme Biotech Co.,Ltd All rights reserved  苏ICP备12014779号-1  Power by: www.300.cn nanjing.300.cn